Sensitization of Human and Rat Nociceptors by Low Dose Morphine is TLR4-dependent.
Ievgen V KhomulaDionéia AraldiPaul G GreenJon D LevinePublished in: Molecular pain (2024)
While opioids remain amongst the most effective treatments for moderate-to-severe pain, their substantial side effect profile remains a major limitation to broader clinical use. One such side effect is opioid-induced hyperalgesia (OIH), which includes a transition from opioid-induced analgesia to pain enhancement. Evidence in rodents supports the suggestion that OIH may be produced by the action of opioids at Toll-like Receptor 4 (TLR4) either on immune cells that, in turn, produce pronociceptive mediators to act on nociceptors, or by a direct action at nociceptor TLR4. And, sub-analgesic doses of several opioids have been shown to induce hyperalgesia in rodents by their action as TLR4 agonists. In the present in vitro patch-clamp electrophysiology experiments, we demonstrate that low dose morphine directly sensitizes human as well as rodent dorsal root ganglion (DRG) neurons, an effect of this opioid analgesic that is antagonized by LPS-RS Ultrapure, a selective TLR4 antagonist. We found that low concentration (100 nM) of morphine reduced rheobase in human (by 36%) and rat (by 26%) putative C-type nociceptors, an effect of morphine that was markedly attenuated by preincubation with LPS-RS Ultrapure. Our findings support the suggestion that in humans, as in rodents, OIH is mediated by the direct action of opioids at TLR4 on nociceptors.
Keyphrases
- toll like receptor
- pain management
- chronic pain
- inflammatory response
- neuropathic pain
- low dose
- endothelial cells
- nuclear factor
- immune response
- high glucose
- spinal cord
- induced pluripotent stem cells
- spinal cord injury
- oxidative stress
- pluripotent stem cells
- diabetic rats
- anti inflammatory
- drug induced
- high dose
- signaling pathway
- ultrasound guided
- stress induced
- quantum dots